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INTRODUCTION
The burden of venous thromboembolism (VTE) is a
challenging problem in the medical management of
cancer patients. The well-known association between
cancer and VTE 1 can now be rigorously studied with
modern molecular techniques 2. Large population-based
epidemiologic studies have shed light on the relative
frequency of VTE and cancer types 3,4, and clinical
trials of cancer therapy have defined additional risk
factors that compound the thrombotic risk 4–6.
VTE AND CANCER PATIENTS
The treatment of cancer patients for VTE has been as-
sociated with a high risk of recurrent thrombosis and
of bleeding complications 7. However, recent data point
to improved patient outcome with the use of long-term
low molecular weight heparin therapy 8,9. Cancer pa-
tients who also have VTE are at increased risk of mor-
tality 10, but there are intriguing suggestions concerning
the benefit of low molecular weight heparin for im-
proved cancer survival 11. A recently published guideline
facilitates the practice of evidence-based VTE preven-
tion and treatment in cancer patients, and sets the stage
for future directions in this important domain 12.
Attendant Problems
The inherent properties of blood vessels, endothelial cells,
adhesion receptors, and soluble plasma coagulation
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proteins render these structures and molecules impor-
tant in the propagation of coagulation and the regula-
tion of cancer-cell growth. Perturbation of these
components by cancer treatment interventions such as
surgery, chemotherapy, and supportive care can fur-
ther exacerbate prothrombotic properties.
Advanced cancer is more often associated with
VTE, as are certain cancer types, including pancreatic,
stomach, brain, lung, and hematologic malignancies.
In cancer patients, VTE is not only a frequent cause of
death, it also identifies a patient population with poor
prognosis, and it is both clinically challenging and fi-
nancially costly to treat. As cancer treatment modalities
evolve, differences in the added thrombogenic risk for
patients also emerge—for example, the addition of anti-
angiogenic therapy is associated with one of the high-
est risks of thrombotic complications.
Optimizing Treatment
Given the strong association of cancer and VTE, how
should thromboprophylaxis for cancer patients be
optimized?
Clearly, as recently reviewed in Current Oncol-
ogy, patients undergoing cancer surgery and those hos-
pitalized for investigations and treatment of cancer are
good candidates for appropriate thromboprophylaxis 13.
Because all currently used anticoagulants are inher-
ently associated with a risk of bleeding and because
they generate added cost, prophylaxis of cancer pa-
tients at lower thrombotic risk cannot be justified at
this time. Probing the role of low molecular weight
heparins in modifying cancer progression should be the
subject of additional well-designed clinical trials. All
cancer-associated VTE should be considered for long-
term low molecular weight heparin therapy, given the
more favourable clinical outcomes seen as compared
with the outcomes seen with traditional oral antico-
agulant therapy.
The recent guidelines from the American Society
of Clinical Oncology underline the importance of
optimizing anticoagulation management of cancer pa-
tients. The practice of appropriate thromboprophylaxis,
up-to-date anticoagulation of cancer-associated VTE,
and participation in good clinical trials evaluatingSOLYMOSS
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cancer and coagulation should routinely be part of our
comprehensive care of cancer patients.
REFERENCES
1. Trousseau A. Phlegmasia alba dolens. Clinique Medicale
l’Hotel-Dieu de Paris. Vol. 3. London: New Sydenham Society;
1865: 695–727.
2. Buller HR, van Doormaal FF, van Sluis GL, Kamphuisen PW.
Cancer and thrombosis: from molecular mechanisms to clinical
presentations. J Thromb Haemost 2007;5(suppl 1):246–54.
3. Levitan N, Dowlati A, Remick SC, et al. Rates of initial and
recurrent thromboembolic disease among patients with malig-
nancy versus those without malignancy. Risk analysis using
Medicare claims data. Medicine (Baltimore) 1999;78:285–91.
4. Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman
GH. Frequency, risk factors, and trends for venous throm-
boembolism among hospitalized cancer patients. Cancer
2007;110:2339–46.
5. Haddad TC, Greeno EW. Chemotherapy-induced thrombosis.
Thromb Res 2006;118:555–68.
6. Zangari M, Barlogie B, Anaissie E, et al. Deep vein thrombosis
in patients with multiple myeloma treated with thalidomide
and chemotherapy: effects of prophylactic and therapeutic
anticoagulation. Br J Haematol 2004;126:715–21.
7. Prandoni P, Lensing AW, Piccioli A, et al Recurrent venous
thromboembolism and bleeding complications during antico-
agulant treatment in patients with cancer and venous thrombo-
sis. Blood 2002;100:3484–8.
8. Lee AY, Levine MN, Baker RI, et al. on behalf of the CLOT
investigators. Low-molecular-weight heparin versus a coumarin
for the prevention of recurrent venous thromboembolism in
patients with cancer. N Engl J Med 2003;349:146–53.
9. Hull RD, Pineo GF, Brant RF, et al. on behalf of the LITE Trial
investigators. Long-term low-molecular-weight heparin versus
usual care in proximal-vein thrombosis patients with cancer.
Am J Med 2006;119:1062–72.
10. Sørensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis
of cancers associated with venous thromboembolism. N Engl J
Med 2000;343:1846–50.
11. Kuderer NM, Khorana AA, Lyman GH, Francis CW. A meta-
analysis and systematic review of the efficacy and safety of
anticoagulants as cancer treatment: impact on survival and bleed-
ing complications. Cancer 2007;110:1149–60.
12. Lyman GH, Khorana AA, Falanga A, et al. American Society of
Clinical Oncology guideline: recommendations for venous throm-
boembolism prophylaxis and treatment in patients with can-
cer. J Clin Oncol 2007;25:5490–505.
13. Brose KMJ, Lee AYY. Cancer-associated thrombosis: preven-
tion and treatment. Curr Oncol 2008;15(suppl 1):S58–67.
Correspondence to: Susan Solymoss, The Montreal
General Hospital, Department of Medicine and On-
cology, McGill University, 1650 Cedar, Montreal, Que-
bec  H3G 1A4.
E-mail: solymosss@muhchem.mcgill.ca